Evidence map›Paper›PMID 29369733›Full record

ReviewExpert review of neurotherapeutics2018

Clinical applications of ultra-high field magnetic resonance imaging in multiple sclerosis.

Matilde Inglese, Lazar Fleysher, Niels Oesingmann, Maria Petracca

Abstract readReview
In one paragraph

Review in Expert review of neurotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Deep whole brain segmentation of 7T structural MRI.Proceedings of SPIE--the International Society for Optical Engineering · 2023
    Article
  8. Improved detection of multiple sclerosis lesions with T2-prepared double inversion recovery at 3T.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2022
    Article
  9. Review
  10. Article
  11. Developmental venous anomalies in patients with multiple sclerosis: is that a coincidence or an ancillary finding?Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Article
  12. Article
  13. Article
  14. The Central Vein Sign in Radiologically Isolated Syndrome.AJNR. American journal of neuroradiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matilde Inglesea Department of Neurology , Icahn School of Medicine , Mount Sinai , NY , USA.
Lazar Fleysherb Department of Radiology , Icahn School of Medicine , Mount Sinai , NY , USA.
Niels Oesingmannd UK Biobank , Stockport , Cheshire , UK.
Maria Petraccaa Department of Neurology , Icahn School of Medicine , Mount Sinai , NY , USA.

Funding

Examining the role of brain sodium content in multiplesclerosis using MRIR01NS099527 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FLEYSHER, LAZAR, LUBLIN, FRED D · 2017 to 2020
$2.1M
NINDS NIH HHS R01 NS099527
6 · The paper itself

Abstract

introductionMagnetic resonance imaging (MRI) is of paramount importance for the early diagnosis of multiple sclerosis (MS) and MRI findings are part of the MS diagnostic criteria. There is a growing interest in the use of ultra-high-field strength -7 Tesla- (7T) MRI to investigate, in vivo, the pathological substrate of the disease. Areas covered: An overview of 7T MRI applications in MS focusing on increased sensitivity for lesion detection, specificity of the central vein sign and better understanding of MS pathophysiology. Implications for disease diagnosis, monitoring and treatment planning are discussed. Expert commentary: 7T MRI provides increased signal-to-noise and contrast-to-noise-ratio that allow higher spatial resolution and better detection of anatomical and pathological features. The high spatial resolution reachable at 7T has been a game changer for neuroimaging applications not only in MS but also in epilepsy, brain tumors, dementia, and neuro-psychiatric disorders. Furthermore, the first 7T device has recently been cleared for clinical use by the food and drug administration.

Indexed as

Cerebral VeinsGray MatterHumansMagnetic Resonance ImagingMultiple SclerosisNeuroimagingSensitivity and SpecificityWhite Mattercentral vein signFDA clearancegray matter lesionsiron imagingMultiple sclerosissodium imagingultra-high field MRIwhite matter lesions

Identifiers

PMID29369733
PMCPMC6300152

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.